

indicates absence of HBsAb in the specimen.

Positive Result:



Two pink / purple coloured bands appear at the Control Region (C) and Test Region (T). This indicates that the specimen contains detectable amount of HBsAb.

Invalid Result:



The test result is invalid if no band appears either at the Control Region (C) or Test Region (T). In such cases, verify the test procedure and repeat the test with a new SBio HBsAb Test device.

PERFORMANCE CHARACTERISTICS

The sensitivity of SBio HBsAb Test is ~30mIU/ml.

REMARKS

1. The deliberate slow reaction kinetics of SBio HBsAb Test is designed to maximize and enhance reaction time between sample capture and tracer elements to improve test sensitivity.
2. Most positive results develop within 10 minutes. However, certain sera sample may take a longer time to flow. Therefore, negatives should be confirmed only at 15 minutes. Do not interpret the results beyond 15 minutes.
3. As with all diagnostic tests, a definitive clinical diagnosis should not be based on the result of a single test, but should only be made by the physician after all clinical and laboratory findings have been evaluated.
4. SBio HBsAb Test should be used as a screening test in clinically suspected cases only, and its results should be confirmed by other

5. supplemental method before taking clinical decisions. Presence of anti HBs generally indicates (a) past HBV infection with immunity (b) Hepatitis B immunisation (c) prophylaxis with Hepatitis B immunoglobulin (d) contact with non-infectious HBsAg. In exceptional cases anti HBs and HBsAg may be detectable in serum at the same time.

WARRANTY

This product is designed to perform as described on the label and package insert. The manufacturer disclaims any implied warranty of use and sale for any other purpose.

BIBLIOGRAPHY

1. Hepatitis B Virus Immunopathology, Chisari F.V., et. al., Springer Semin Immunopathol, 1995; 17(2-3): 261-81.
2. Hepatitis B Virus Taxonomy and Hepatitis B Virus Genotypes, Schaefer S., et. al., World J. Gastroenterol, 2007, Jan 7;13(1): 14-21.
3. Relevance of Hepatitis B Virus Genome Variability in Organ Transplantation, Samad Amini-Bavil-Olyae, et. al., Hepatitis Monthly 2007; 7(1): 35-41.
4. Risk Factors in Chronic Hepatitis B Infection: A Case-Control Study, Shahnaz Sali M.D., et. al., Hepatitis Monthly 2005; 5(4): 109-115.
5. Hepatitis B e Antigen-Negative Chronic Hepatitis B, Maryam Vaez Jalali, et. al., Hepatitis Monthly 2006, 6(1): 31-35.
6. Source and Response of Antibody to Hepatitis B Vaccine in Hemodialysis Patients, Zohreh Aminzadeh, et. al., Hepatitis Monthly, 2007; 7(1): 33-34.
7. What Level of Hepatitis B Antibody is Protective?, Jack AD, et. al., J. Infect. Dis. 1999 Feb; 179(2): 489-92.



Singapore
Biosciences PTE Ltd.

11 Yishun Street 51, 304-23, The Criterion, Singapore 767971